Promyelocytic leukemia protein induces arsenic trioxide resistance through regulation of aldehyde dehydrogenase 3 family member A1 in hepatocellular carcinoma

Cancer Letters

Volumn 366, Issue 1, 2015, Pages 112-122

  Zhang, Xin ^a,b   Yang, Xin Rong ^a,b   Sun, Chao ^a,b   Hu, Bo ^a,b   Sun, Yun Fan ^a,b   Huang, Xiao Wu ^a,b   Wang, Zheng ^a,b   He, Yi Feng ^a,b   Zeng, Hai Ying ^a   Qiu, Shuang Jian ^a,b   Cao, Ya ^b,c   Fan, Jia ^a,b   Zhou, Jian ^a,b  

^a FUDAN UNIVERSITY   (China)

^b BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^c Central South University   (China)

Author keywords

Aldehyde dehydrogenase 3 family member A1; Drug resistance; Promyelocytic leukemia protein; Reactive oxygen species; Tumor growth

Indexed keywords

ALDEHYDE DEHYDROGENASE; ALDH3A1 PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; NUCLEAR PROTEIN; ORGANOARSENIC DERIVATIVE; OXIDE; PML PROTEIN, HUMAN; TRANSCRIPTION FACTOR; TUMOR SUPPRESSOR PROTEIN;

ADULT; AGED; ANTAGONISTS AND INHIBITORS; CARCINOMA, HEPATOCELLULAR; DRUG RESISTANCE; FEMALE; GENETICS; HUMAN; LIVER NEOPLASMS; MALE; MIDDLE AGED; PHYSIOLOGY;

ADULT; AGED; ALDEHYDE DEHYDROGENASE; ANTINEOPLASTIC AGENTS; ARSENICALS; CARCINOMA, HEPATOCELLULAR; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NUCLEAR PROTEINS; OXIDES; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS;

EID: 84937520191     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2015.06.014     Document Type: Article

References (41)

1. Torre L.A., Bray F., Siegel R.L., Ferlay J., Lortet-Tieulent J., Jemal A. Global cancer statistics, 2012. CA Cancer J. Clin 2015, 65:87-108.
2. Forner A., Llovet J.M., Bruix J. Hepatocellular carcinoma. Lancet 2012, 379:1245-1255.
3. Hollebecque A., Malka D., Ferte C., Ducreux M., Boige V. Systemic treatment of advanced hepatocellular carcinoma: from disillusions to new horizons. Eur. J. Cancer 2015, 51:327-339.
4. Worns M.A., Galle P.R. HCC therapies - lessons learned. Nat. Rev. Gastroenterol. Hepatol 2014, 11:447-452.
5. Bruix J., Gores G.J., Mazzaferro V. Hepatocellular carcinoma: clinical frontiers and perspectives. Gut 2014, 63:844-855.
6. Lo-Coco F., Avvisati G., Vignetti M., Thiede C., Orlando S.M., Iacobelli S., et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N. Engl. J. Med 2013, 369:111-121.
7. Zhang X., Jia S., Yang S., Yang Y., Yang T., Yang Y. Arsenic trioxide induces G2/M arrest in hepatocellular carcinoma cells by increasing the tumor suppressor PTEN expression. J. Cell. Biochem 2012, 113:3528-3535.
8. Alarifi S., Ali D., Alkahtani S., Siddiqui M.A., Ali B.A. Arsenic trioxide-mediated oxidative stress and genotoxicity in human hepatocellular carcinoma cells. Onco Targets Ther 2013, 6:75-84.
9. Litzow M.R. Arsenic trioxide. Expert Opin. Pharmacother 2008, 9:1773-1785.
10. Lin C.C., Hsu C., Hsu C.H., Hsu W.L., Cheng A.L., Yang C.H. Arsenic trioxide in patients with hepatocellular carcinoma: a phase II trial. Invest. New Drugs 2007, 25:77-84.
11. Altucci L., Gronemeyer H. The promise of retinoids to fight against cancer. Nat. Rev. Cancer 2001, 1:181-193.
12. Shao W., Fanelli M., Ferrara F.F., Riccioni R., Rosenauer A., Davison K., et al. Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells. J. Natl Cancer Inst 1998, 90:124-133.
13. Sun H.X., Xu Y., Yang X.R., Wang W.M., Bai H., Shi R.Y., et al. Hypoxia inducible factor 2 alpha inhibits hepatocellular carcinoma growth through the transcription factor dimerization partner 3/E2F transcription factor 1-dependent apoptotic pathway. Hepatology 2013, 57:1088-1097.
14. Yang X.R., Xu Y., Yu B., Zhou J., Li J.C., Qiu S.J., et al. CD24 is a novel predictor for poor prognosis of hepatocellular carcinoma after surgery. Clin. Cancer Res 2009, 15:5518-5527.
15. Lee H.E., Jee C.D., Kim M.A., Lee H.S., Lee Y.M., Lee B.L., et al. Loss of promyelocytic leukemia protein in human gastric cancers. Cancer Lett 2007, 247:103-109.
16. Vincenzi B., Santini D., Schiavon G., Frezza A.M., Silletta M., Crucitti P., et al. PML expression in soft tissue sarcoma: prognostic and predictive value in alkylating agents/antracycline-based first line therapy. J. Cell. Physiol 2012, 227:1657-1662.
17. Li J.C., Yang X.R., Sun H.X., Xu Y., Zhou J., Qiu S.J., et al. Up-regulation of Kruppel-like factor 8 promotes tumor invasion and indicates poor prognosis for hepatocellular carcinoma. Gastroenterology 2010, 139:2146-2157.e12.
18. Kito M., Matsumoto K., Wada N., Sera K., Futatsugawa S., Naoe T., et al. Antitumor effect of arsenic trioxide in murine xenograft model. Cancer Sci 2003, 94:1010-1014.
19. Huang J., Zheng D.L., Qin F.S., Cheng N., Chen H., Wan B.B., et al. Genetic and epigenetic silencing of SCARA5 may contribute to human hepatocellular carcinoma by activating FAK signaling. J. Clin. Invest 2010, 120:223-241.
20. Zhang B., Peng X., Li G., Xu Y., Xia X., Wang Q. Oxidative stress is involved in Patulin induced apoptosis in HEK293 cells. Toxicon 2014, 94:1-7.
21. Eisenhauer E.A., Therasse P., Bogaerts J., Schwartz L.H., Sargent D., Ford R., et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 2009, 45:228-247.
22. Emadi A., Gore S.D. Arsenic trioxide - an old drug rediscovered. Blood Rev 2010, 24:191-199.
23. Miller W.H., Schipper H.M., Lee J.S., Singer J., Waxman S. Mechanisms of action of arsenic trioxide. Cancer Res 2002, 62:3893-3903.
24. Parajuli B., Fishel M.L., Hurley T.D. Selective ALDH3A1 inhibition by benzimidazole analogues increase mafosfamide sensitivity in cancer cells. J. Med. Chem 2014, 57:449-461.
25. Wang Z.Y., Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood 2008, 111:2505-2515.
26. Rabellino A., Scaglioni P.P. PML degradation: multiple ways to eliminate PML. Front. Oncol 2013, 3:60.
27. Kim K.B., Bedikian A.Y., Camacho L.H., Papadopoulos N.E., McCullough C. A phase II trial of arsenic trioxide in patients with metastatic melanoma. Cancer 2005, 104:1687-1692.
28. Tarhini A.A., Kirkwood J.M., Tawbi H., Gooding W.E., Islam M.F., Agarwala S.S. Safety and efficacy of arsenic trioxide for patients with advanced metastatic melanoma. Cancer 2008, 112:1131-1138.
29. Vuky J., Yu R., Schwartz L., Motzer R.J. Phase II trial of arsenic trioxide in patients with metastatic renal cell carcinoma. Invest. New Drugs 2002, 20:327-330.
30. Mazza M., Pelicci P.G. Is PML a tumor suppressor?. Front. Oncol 2013, 3:174.
31. Bernardi R., Guernah I., Jin D., Grisendi S., Alimonti A., Teruya-Feldstein J., et al. PML inhibits HIF-1alpha translation and neoangiogenesis through repression of mTOR. Nature 2006, 442:779-785.
32. Reineke E.L., Liu Y., Kao H.Y. Promyelocytic leukemia protein controls cell migration in response to hydrogen peroxide and insulin-like growth factor-1. J. Biol. Chem 2010, 285:9485-9492.
33. Dellaire G., Bazett-Jones D.P. PML nuclear bodies: dynamic sensors of DNA damage and cellular stress. Bioessays 2004, 26:963-977.
34. Geoffroy M.C., Chelbi-Alix M.K. Role of promyelocytic leukemia protein in host antiviral defense. J. Interferon Cytokine Res 2011, 31:145-158.
35. Jackson B., Brocker C., Thompson D.C., Black W., Vasiliou K., Nebert D.W., et al. Update on the aldehyde dehydrogenase gene (ALDH) superfamily. Hum. Genomics 2011, 5:283-303.
36. Lassen N., Bateman J.B., Estey T., Kuszak J.R., Nees D.W., Piatigorsky J., et al. Multiple and additive functions of ALDH3A1 and ALDH1A1: cataract phenotype and ocular oxidative damage in Aldh3a1(-/-)/Aldh1a1(-/-) knock-out mice. J. Biol. Chem 2007, 282:25668-25676.
37. Kapahi P., Takahashi T., Natoli G., Adams S.R., Chen Y., Tsien R.Y., et al. Inhibition of NF-kappa B activation by arsenite through reaction with a critical cysteine in the activation loop of Ikappa B kinase. J. Biol. Chem 2000, 275:36062-36066.
38. Galimberti S., Guerrini F., Salvi F., Petrini I., Gioia D., Messa E., et al. Arsenic trioxide and ascorbic acid interfere with the BCL2 family genes in patients with myelodysplastic syndromes: an ex-vivo study. J. Hematol. Oncol 2012, 5:53.
39. Dizaji M.Z., Malehmir M., Ghavamzadeh A., Alimoghaddam K., Ghaffari S.H. Synergistic effects of arsenic trioxide and silibinin on apoptosis and invasion in human glioblastoma U87MG cell line. Neurochem. Res 2012, 37:370-380.
40. Rojewski M.T., Korper S., Schrezenmeier H. Arsenic trioxide therapy in acute promyelocytic leukemia and beyond: from bench to bedside. Leuk. Lymphoma 2004, 45:2387-2401.
41. Sertel S., Tome M., Briehl M.M., Bauer J., Hock K., Plinkert P.K., et al. Factors determining sensitivity and resistance of tumor cells to arsenic trioxide. PLoS ONE 2012, 7:e35584.